Proteomics International Laboratories (ASX: PIQ) is making great headway! CEO interview
On 5 June 2025, we spoke with Dr. Richard Lipscombe, CEO of Proteomics International Laboratories (ASX: PIQ), about the strong commercial prospects of his PromarkerD diagnostic for kidney disease now that the product is available for clinical use. We also spoke about the valuable pipeline that it's building, with diagnostics for endometriosis and esophageal cancer. Proteomics' platform, allowing the easy characterisation of proteins, has considerable upside that is only now being tapped.
